Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve outcomes for people living with hereditary angioedema.

In January 2021, the Government published the United Kingdom Rare Diseases Framework, to improve the lives of those living with rare diseases over the next five years. The NHS Immunology and Allergy Clinical Reference Group is revising the current commissioning policies ‘Treatment of Acute Attacks in Hereditary Angioedema (Adult)’ and ‘Plasma-derived C1-esterase inhibitor for Prophylactic treatment of hereditary angioedema (HAE) types I and II’ to reduce health inequalities and improve outcomes for people living with HAE in England. In addition, the National Health Service Commercial Medicines Unit is developing a procurement framework for medicines to treat HAE for launch in summer 2022.